Press release
Dyspepsia Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Astellas Pharma Inc, Forest Laboratories, EMS, Dong-A ST Co., Ltd., Xian-Janssen Pharmaceutical Ltd
"Dyspepsia Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/dyspepsia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dyspepsia Market.
The Dyspepsia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Dyspepsia Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Dyspepsia treatment therapies with a considerable amount of success over the years.
*
Dyspepsia companies working in the treatment market are Astellas Pharma Inc, Forest Laboratories, EMS, Dong-A ST Co., Ltd., Xian-Janssen Pharmaceutical Ltd., Materia Medica Holding, Novartis, Eisai China Inc., Zeria Pharmaceutical, Dexa Medica Group, Eisai Co., Ltd., Korea United Pharm. Inc., Daewoong Pharmaceutical, Johnson & Johnson, and others, are developing therapies for the Dyspepsia treatment
*
Emerging Dyspepsia therapies in the different phases of clinical trials are- Itopride Hydrochloride, FDC Bromopride, Motilitone, YM443, Domperidone, Kolofort, Tegaserod, Cinitapride, Z-338, DLBS2411, Rabeprazole, UI05MSP015CT, DWJ1252, Imonogas, and others are expected to have a significant impact on the Dyspepsia market in the coming years.
*
In November 2024, The FDA has approved Emrosi Trademark (minocycline hydrochloride extended-release capsules) for treating inflammatory lesions (papules and pustules) of rosacea in adults. In the Phase III MVOR-2 trial, 60% of patients on Emrosi achieved IGA success at week 16, compared to 31% in the doxycycline group (treatment difference: 28% [95% CI, 17-39]) and 27% in the placebo group (treatment difference: 34% [95% CI, 21-47]). The mean reduction in inflammatory lesion counts was -18.1 with Emrosi, -14.6 with doxycycline, and -11.2 with placebo. The most commonly reported side effect was dyspepsia.
Dyspepsia Overview
Dyspepsia refers to a group of symptoms that are related to the upper part of the digestive tract, particularly the stomach. Commonly known as indigestion, dyspepsia can manifest as discomfort or pain in the upper abdomen.
Get a Free Sample PDF Report to know more about Dyspepsia Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/dyspepsia-pipeline-insight [https://www.delveinsight.com/report-store/dyspepsia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Dyspepsia Drugs Under Different Phases of Clinical Development Include:
*
YM443: Astellas Pharma Inc
*
Itopride Hydrochloride: Forest Laboratories
*
FDC Bromopride: EMS
*
Motilitone: Dong-A ST Co., Ltd.
*
YM443: Astellas Pharma Inc
*
Domperidone: Xian-Janssen Pharmaceutical Ltd.
*
Kolofort: Materia Medica Holding
*
Tegaserod: Novartis
*
Cinitapride: Eisai China Inc.
*
Z-338: Zeria Pharmaceutical
*
DLBS2411: Dexa Medica Group
*
Rabeprazole: Eisai Co., Ltd.
*
UI05MSP015CT: Korea United Pharm. Inc.
*
DWJ1252: Daewoong Pharmaceutical
*
Imonogas: Johnson & Johnson
Dyspepsia Route of Administration
Dyspepsia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Parenteral
*
Intravenous
*
Subcutaneous
*
Topical
Dyspepsia Molecule Type
Dyspepsia Products have been categorized under various Molecule types, such as
*
Monoclonal Antibody
*
Peptides
*
Polymer
*
Small molecule
*
Gene therapy
Dyspepsia Pipeline Therapeutics Assessment
*
Dyspepsia Assessment by Product Type
*
Dyspepsia By Stage and Product Type
*
Dyspepsia Assessment by Route of Administration
*
Dyspepsia By Stage and Route of Administration
*
Dyspepsia Assessment by Molecule Type
*
Dyspepsia by Stage and Molecule Type
DelveInsight's Dyspepsia Report covers around 2+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Dyspepsia product details are provided in the report. Download the Dyspepsia pipeline report to learn more about the emerging Dyspepsia therapies [https://www.delveinsight.com/sample-request/dyspepsia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Dyspepsia Therapeutics Market include:
Key companies developing therapies for Dyspepsia are - Bayer, Sumitomo, Cadila Pharmaceuticals, Teva, Johnson & Johnson, Pfizer, Sanofi, AstraZeneca, Jiangsu Aosaikang Pharma, Eisai, Kyowa Kirin Pharmaceuticals, Hanmi Pharm, and others.
Dyspepsia Pipeline Analysis:
The Dyspepsia pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Dyspepsia with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dyspepsia Treatment.
*
Dyspepsia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Dyspepsia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dyspepsia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Dyspepsia drugs and therapies [https://www.delveinsight.com/sample-request/dyspepsia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Scope of Dyspepsia Pipeline Drug Insight
*
Coverage: Global
*
Key Dyspepsia Companies: Astellas Pharma Inc, Forest Laboratories, EMS, Dong-A ST Co., Ltd., Astellas Pharma Inc, Xian-Janssen Pharmaceutical Ltd., Materia Medica Holding, Novartis, Eisai China Inc., Zeria Pharmaceutical, Dexa Medica Group, Eisai Co., Ltd., Korea United Pharm. Inc., Daewoong Pharmaceutical, Johnson & Johnson, and others
*
Key Dyspepsia Therapies: Itopride Hydrochloride, FDC Bromopride, Motilitone, YM443, Domperidone, Kolofort, Tegaserod, Cinitapride, Z-338, DLBS2411, Rabeprazole, UI05MSP015CT, DWJ1252, Imonogas, and others
*
Dyspepsia Therapeutic Assessment: Dyspepsia current marketed and Dyspepsia emerging therapies
*
Dyspepsia Market Dynamics: Dyspepsia market drivers and Dyspepsia market barriers
Request for Sample PDF Report for Dyspepsia Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/dyspepsia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Dyspepsia Report Introduction
2. Dyspepsia Executive Summary
3. Dyspepsia Overview
4. Dyspepsia- Analytical Perspective In-depth Commercial Assessment
5. Dyspepsia Pipeline Therapeutics
6. Dyspepsia Late Stage Products (Phase II/III)
7. Dyspepsia Mid Stage Products (Phase II)
8. Dyspepsia Early Stage Products (Phase I)
9. Dyspepsia Preclinical Stage Products
10. Dyspepsia Therapeutics Assessment
11. Dyspepsia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Dyspepsia Key Companies
14. Dyspepsia Key Products
15. Dyspepsia Unmet Needs
16 . Dyspepsia Market Drivers and Barriers
17. Dyspepsia Future Perspectives and Conclusion
18. Dyspepsia Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=dyspepsia-pipeline-2025-therapies-moa-insights-and-key-clinical-trial-updates-by-delveinsight-astellas-pharma-inc-forest-laboratories-ems-donga-st-co-ltd-xianjanssen-pharmaceutical-ltd]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dyspepsia Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Astellas Pharma Inc, Forest Laboratories, EMS, Dong-A ST Co., Ltd., Xian-Janssen Pharmaceutical Ltd here
News-ID: 4174264 • Views: …
More Releases from ABNewswire
The Great Unroboting: AI-Text-Humanizer.com Improves the Human-AI Collaboration …
MUNICH, GERMANY - September 30, 2025 - As companies hurry to integrate Artificial Intelligence into their workflows, a critical challenge emerged: The loss of the human touch. From sales emails to internal memos - AI-generated communication is often generic, impersonal but also ineffective. AI-Text-Humanizer.com started its enterprise platform to solve this problem - to improve human-AI collaboration.
The drive for AI-powered efficiency has created a corporate communications crisis. Sales outreach emails…
Phenix City Medical Practice Announces Expanded Healthcare Services, Addressing …
Preferred Medical Group, Phenix City, announces the expansion of its healthcare services and improved patient access, addressing community demand for comprehensive medical care with integrated pediatric, adult, and therapeutic services under one roof.
Preferred Medical Group, Phenix City [https://preferredmedgroup.com/], has announced significant enhancements to its healthcare services, responding to increased community demand for accessible and comprehensive medical care. The medical practice, located at 3700 South Railroad Street, has introduced streamlined patient…
Auburn Medical Practice Expands Integrated Care Model as Primary Care Doctor Add …
Preferred Medical Group - Auburn expands ADHD services and integrated care model, offering comprehensive family medicine, behavioral health, and specialized attention disorder treatment in one convenient East Alabama location.
Preferred Medical Group - Auburn [https://preferredmedgroup.com/] has announced significant enhancements to its integrated healthcare services, responding to increased demand for ADHD treatment and comprehensive family medical care in East Alabama. The Auburn location, situated at 318 Samford Village Court, Suite 100, now…
Local ADHD Doctor Program Launches at Preferred Medical Group - Opelika for East …
Preferred Medical Group - Opelika launches an integrated ADHD treatment program that combines pediatric care, psychiatry, and therapy services to address regional healthcare needs for East Alabama families.
Opelika healthcare providers have taken a significant step toward addressing the growing need for specialized attention deficit hyperactivity disorder services in East Alabama. Preferred Medical Group - Opelika [https://preferredmedgroup.com/] has announced the expansion of comprehensive ADHD treatment programs, integrating pediatric care with behavioral…
More Releases for Dyspepsia
Functional Dyspepsia Market Insights and Future Outlook
Introduction
Functional Dyspepsia (FD), often referred to as non-ulcer dyspepsia, is a chronic disorder characterized by persistent or recurrent pain and discomfort in the upper abdomen without any identifiable structural cause. Symptoms include bloating, nausea, early satiety, and epigastric pain, which significantly impact quality of life. FD is one of the most common functional gastrointestinal disorders, affecting millions worldwide, yet remains underdiagnosed and undertreated due to overlapping symptoms with other GI…
Functional Dyspepsia Market to Set Phenomenal Growth From 2025 to 2034
Introduction
Functional Dyspepsia (FD), also known as non-ulcer dyspepsia, is a common chronic disorder of the upper gastrointestinal tract characterized by epigastric pain, postprandial fullness, bloating, and early satiety. Unlike peptic ulcers or GERD, functional dyspepsia has no identifiable structural cause, making diagnosis and treatment challenging.
The condition affects millions globally, with a strong link to poor dietary habits, stress, lifestyle changes, and Helicobacter pylori infection. While treatments include acid suppressants, prokinetics,…
Dyspepsia Drug Market Scope, and Competitive Analysis Forecast Through 2024-2031
The Dyspepsia Drug Market study by DataM Intelligence offer an in-depth analysis of the market, presenting insightful observations, statistics, historical data, and industry-validated market insights. The report delves into the competitive positioning of key companies, examining factors such as product offerings, pricing strategies, financial health, product portfolios, growth initiatives, and geographical reach.
Get a Free Sample PDF - https://datamintelligence.com/download-sample/dyspepsia-drugs-market
What is the projected growth rate (CAGR) of the Global Dyspepsia market from…
NA Dyspepsia Drug Market 2024 To Witness Amazing Growth By 2032
NA Dyspepsia Drug Market Size 2024[Latest Report]:
North America dyspepsia drug market is expected to reach USD 539,245.09 thousand by 2030 from USD 351,924.80 thousand in 2022, growing at a CAGR of 5.6% during the forecast period of 2023 to 2030.
The NA Dyspepsia Drug Market 2024 Report makes available the current and forthcoming technical and financial details of the industry. This NA Dyspepsia Drug Market Report covers the Types, Applications, manufacturer…
Dyspepsia Market Size to Reach USD 2268.8 million by 2032
Introduction
Definition of Dyspepsia: Dyspepsia, commonly known as indigestion, refers to a condition characterized by discomfort or pain in the upper abdomen. It is not a specific disease but rather a set of symptoms that can include bloating, nausea, and burping. Dyspepsia is often associated with eating and can be a chronic or recurrent condition.
Symptoms and Causes: The primary symptoms of dyspepsia include a burning sensation or pain in the upper…
Functional Dyspepsia Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Functional Dyspepsia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Functional Dyspepsia, historical and forecasted epidemiology as well as the Functional Dyspepsia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Functional Dyspepsia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Functional Dyspepsia market size from…
